To view or add a comment, sign in New EASO Framework for Obesity Pharmacotherapy Exciting update from the European Association for the Study of Obesity (EASO), just published in Nature Medicine: Framework for the pharmacological treatment of obesity and its complications This landmark commentary highlights obesity as a chronic, multifactorial, and relapsing disease requiring personalized, complication-oriented treatment not merely weight reduction
RFS, Relapse-free survival
Symptomatic treatment of migraine in children: a systematic review of medication trials
By acting on the brains appetite centers and the digestive tract, GLP-1 medications can: Suppress appetite and reduce food cravings Slow gastric emptying, making you feel fuller for longer Improve insulin sensitivity and stabilize blood sugar Support significant and sustained weight loss, sometimes rivaling bariatric surgery These medications are typically prescribed as weekly injections and are most effective when combined with healthy lifestyle changes
Acta 1842 , 446462 (2014)
Frier Levitt regulatory attorneys experienced in FDA law and pharmacy law are available to assist clients with strategic advisory, regulatory compliance and enforcement defense services in the GLP-1, compounded drug and peptide space as regulations and enforcement in this sector continues to evolve